source
- Eli Lilly's retatrutide shows over a third of patients lose 25%+ weight in phase 3 trialEli Lilly presented detailed results from its phase 3 retatrutide trial at the European Association for the Study of Diabetes meeting in Milan and in a recent Lancet publication. The study enrolle…
- GSK pays $12 million to Wave for liver-focused siRNA program, expanding its RNA drug pipelineGSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program that emerged from their long‑running collaboration. The payment follows a 2022 agreement in which GSK pa…